NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 31, 2024 09:00 ET
|
NAYA Biosciences, Inc.
SARASOTA, Fla. and MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in...
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
October 24, 2024 09:00 ET
|
NAYA Biosciences, Inc.
SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in...
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
October 21, 2024 09:00 ET
|
INVO Bioscience
SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility,...
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
October 14, 2024 09:18 ET
|
INVO Bioscience
SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing...
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
January 23, 2024 08:00 ET
|
NAYA Biosciences
NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed by Florida Biotechnologies, Inc. & the...
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
January 17, 2024 08:00 ET
|
NAYA Biosciences
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...